- decision psychology
- probability/bayes
- test performance
- value of information
- mathematical models
- state-transition
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- economics/finance
- health/medicine
- military/defense
- europe
Resources Repository
-
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | State-Transition | Value of Information | Economics/Finance | Europe | Infectious Diseases | Policy/Regulation | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Mathematical Models | Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Europe | Preferences/Values | Health Outcomes | Health Systems | Science/Technology | North America -
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Europe | Evidence Synthesis | Chronic Disease/Risk -
BriefPublication 2023Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality into CEA
This study addresses the limitations of conventional static approaches in health economic modeling by proposing …
This study addresses the limitations of conventional static approaches in health economic modeling by proposing a dynamic general population mortality modeling method. Using a replication of the axicabtagene ciloleucel model from NICE appraisal TA559, the authors demonstrate the potential impact of this approach on estimating life-years and cost-effectiveness. The model utilizes national mortality projections and updates mortality rates annually, considering different assumptions around age distribution. Results show that incorporating dynamic calculations increases undiscounted life-years attributed…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Europe -
Tutorial/PrimerPublication, Teaching Resource 2023Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: Tutorial
The study examines the utility of excess hazard (EH) methods in reducing model uncertainty when …
The study examines the utility of excess hazard (EH) methods in reducing model uncertainty when estimating long-term survival in cost-effectiveness analyses. Using a case study of breast cancer patients, standard parametric survival models were compared with EH methods incorporating general population mortality rates, with and without a cure parameter. Results showed substantial variability in survival extrapolations across standard models, while EH methods, particularly EH cure models, significantly reduced uncertainty. Long-term treatment effects approached null for…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Europe | Chronic Disease/Risk -
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Europe | Priority Setting/Ethics | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Government/Law -
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Europe | Preferences/Values | Costing Methods | Health Outcomes | Infectious Diseases | Clinical Care | Culture/Society | Science/Technology | North America -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Europe | Priority Setting/Ethics | Health Systems | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
Cost-Effectiveness Analysis | State-Transition | Health/Medicine | Europe | Chronic Disease/Risk | Mental Health